Comparison of Oral vs Intravenous Iron Therapy for the Treatment of Postpartum Anemia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07340450

Enrollment

122

Registered

2026-01-14

Start date

2025-02-18

Completion date

2025-08-18

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Anaemia

Brief summary

Postpartum anemia is a common condition associated with adverse maternal outcomes. This study aimed to compare the effectiveness of oral iron therapy versus intravenous iron therapy in women with postpartum anemia.

Detailed description

This randomized, open-label, parallel-group study was conducted at Shahida Islam Medical College and Hospital, Lodhran, Pakistan. Women diagnosed with postpartum anemia who fulfilled the eligibility criteria were randomly allocated using a lottery method to receive either intravenous iron (ferric carboxymaltose) or oral iron therapy (ferrous sulfate). The primary outcome was the change in hemoglobin level from baseline to 6 weeks of follow-up.

Interventions

DRUGFerric Carboxy Maltose

Participants received Intravenous iron i.e ferric carboxymaltose (≤1,000 mg) were given to patients in Group A either as a single dose or as two doses spaced three days apart in 100 milliliters of 0.9% normal saline during a half-hour period.

DRUGFerrous Sulfate

Participants given tablet Ferrous sulfate, 325 mg orally three times a day.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

1. All women with postpartum anaemia as per operational definition i.e Haemoglobin \<11 g/dl at 24 hours after delivery (either caesarean or SVD). 2. Age 20-40 years. 3. BMI 19-25. 4. Pre-operative haemoglobin \>10 g/dl. 5. Both primiparous and multiparous. 6. Both primigravida and multigravida. \-

Exclusion criteria

1. Iron Intolerance or previous history of allergy to iron 2. Parenteral Iron hypersensitivity 3. Patients with thalassemia 4. Indication of blood transfusion 5. Patients with bleeding/ clotting disorders 6. Patients with postpartum haemorrhage 7. Patients with chronic diseases.

Design outcomes

Primary

Measure	Time frame
Change in hemoglobin level	Baseline to 6 weeks postpartum

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026